-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Livzon Group disclosed its third quarter report for 2021.
In the first three quarters, the company realized operating income of RMB 9.
369 billion, a year-on-year increase of 18.
22%; net profit attributable to shareholders of listed companies was RMB 1.
453 billion, a year-on-year increase of 2.
19%; basic per share The income is 1.
55 yuan
.
It is worth noting that in the first three quarters, under the background of the overall performance of Livzon Group, diagnostic reagents and equipment products fell 52.
64% year-on-year, and only achieved revenue of 552 million yuan
.
In this regard, the industry believes that this is due to the fact that with the advent of the post-epidemic era, pharmaceutical companies that mainly produce protective equipment have basically bid farewell to the period of "great profits", and the profit growth rate has begun to slow down
.
In 2020, with the outbreak of the epidemic, people's demand for protective and testing supplies has surged, and related companies will naturally make a lot of money
.
However, as the epidemic has been brought under control, the demand for protection, testing and other supplies has begun to decrease, which has slowed down the growth of a large number of companies' related businesses
.
This trend can also be clearly seen from the recent three quarterly reports of pharmaceutical companies
.
As of October 26, according to choice statistics, a total of 40 companies in the medical industry have released three quarterly reports, and a total of 76 companies in the pharmaceutical manufacturing industry have released three quarterly reports
.
From an overall point of view, the performance of pharmaceutical companies in the third quarter showed a trend of polarization.
As a large number of companies continued to rise in performance, some companies showed a significant slowdown or even a decline in their growth rates in the post-epidemic era
.
Specifically, according to incomplete statistics, among the pharmaceutical companies that released the third quarter reports, a total of 18 companies’ net profit in the first three quarters increased by more than 100% year-on-year; Jiaying Pharmaceutical, Northeast Pharmaceutical, Taiji Group and Harbin Sanlian Net profit in the third quarter increased by 1,000% year-on-year; in addition, there were seven pharmaceutical companies whose revenue in the first three quarters exceeded 10 billion yuan
.
Among them, Tai Chi Group is one of the pharmaceutical companies with a relatively large increase in revenue and net profit in the three quarterly reports that have been published
.
Relying on the dual track layout of traditional Chinese medicine and western medicine, Tai Chi Group achieved operating income of 9.
570 billion yuan from January to September this year, an increase of 10.
70% year-on-year; net profit attributable to shareholders of listed companies was 248 million yuan, an increase of 1425.
54% year-on-year
.
It is worth mentioning that in the third quarter alone, its revenue reached 3.
126 billion yuan, and its net profit reached 171 million yuan, an increase of 2733.
26% year-on-year
.
But at the same time, there are also many companies whose performance has not improved under the influence of the epidemic, especially some companies that focus on protection and testing supplies, and even suffered losses
.
It is reported that the net profit of 17 companies in the first three quarters fell year-on-year
.
For example, Winner Medical achieved operating income of 5.
82 billion yuan in the first three quarters, a year-on-year decrease of 38.
89%; net profit attributable to shareholders of listed companies was 1.
104 billion yuan, a year-on-year decrease of 64.
95%; basic earnings per share were 2.
59 yuan
.
Among them, the operating income in the third quarter was 1.
76 billion yuan, a year-on-year decrease of 67.
06%; the net profit attributable to shareholders of listed companies was 343 million yuan, a year-on-year decrease of 83.
8%
.
In addition, on October 25, Zhende Medical disclosed its three-quarter report for 2021, showing that its revenue and net profit attributable to the first three quarters of this year also fell
.
Data shows that Zhende Medical's operating income in the first three quarters of this year was approximately 3.
863 billion yuan, a year-on-year decrease of 52.
41%; the corresponding realized net profit was approximately 483 million yuan, a year-on-year decrease of 77%
.
Regarding the decline in performance and operating income, Zhende Medical made it clear that it was mainly due to the impact of the epidemic in the same period last year.
The company's sales of anti-epidemic protective equipment increased significantly.
However, as the domestic epidemic situation has been effectively controlled, domestic and foreign epidemic prevention products have relatively sufficient production capacity.
, Caused by the return of the price of anti-epidemic protective equipment
.
In the first three quarters, the company realized operating income of RMB 9.
369 billion, a year-on-year increase of 18.
22%; net profit attributable to shareholders of listed companies was RMB 1.
453 billion, a year-on-year increase of 2.
19%; basic per share The income is 1.
55 yuan
.
It is worth noting that in the first three quarters, under the background of the overall performance of Livzon Group, diagnostic reagents and equipment products fell 52.
64% year-on-year, and only achieved revenue of 552 million yuan
.
In this regard, the industry believes that this is due to the fact that with the advent of the post-epidemic era, pharmaceutical companies that mainly produce protective equipment have basically bid farewell to the period of "great profits", and the profit growth rate has begun to slow down
.
In 2020, with the outbreak of the epidemic, people's demand for protective and testing supplies has surged, and related companies will naturally make a lot of money
.
However, as the epidemic has been brought under control, the demand for protection, testing and other supplies has begun to decrease, which has slowed down the growth of a large number of companies' related businesses
.
This trend can also be clearly seen from the recent three quarterly reports of pharmaceutical companies
.
As of October 26, according to choice statistics, a total of 40 companies in the medical industry have released three quarterly reports, and a total of 76 companies in the pharmaceutical manufacturing industry have released three quarterly reports
.
From an overall point of view, the performance of pharmaceutical companies in the third quarter showed a trend of polarization.
As a large number of companies continued to rise in performance, some companies showed a significant slowdown or even a decline in their growth rates in the post-epidemic era
.
Specifically, according to incomplete statistics, among the pharmaceutical companies that released the third quarter reports, a total of 18 companies’ net profit in the first three quarters increased by more than 100% year-on-year; Jiaying Pharmaceutical, Northeast Pharmaceutical, Taiji Group and Harbin Sanlian Net profit in the third quarter increased by 1,000% year-on-year; in addition, there were seven pharmaceutical companies whose revenue in the first three quarters exceeded 10 billion yuan
.
Among them, Tai Chi Group is one of the pharmaceutical companies with a relatively large increase in revenue and net profit in the three quarterly reports that have been published
.
Relying on the dual track layout of traditional Chinese medicine and western medicine, Tai Chi Group achieved operating income of 9.
570 billion yuan from January to September this year, an increase of 10.
70% year-on-year; net profit attributable to shareholders of listed companies was 248 million yuan, an increase of 1425.
54% year-on-year
.
It is worth mentioning that in the third quarter alone, its revenue reached 3.
126 billion yuan, and its net profit reached 171 million yuan, an increase of 2733.
26% year-on-year
.
But at the same time, there are also many companies whose performance has not improved under the influence of the epidemic, especially some companies that focus on protection and testing supplies, and even suffered losses
.
It is reported that the net profit of 17 companies in the first three quarters fell year-on-year
.
For example, Winner Medical achieved operating income of 5.
82 billion yuan in the first three quarters, a year-on-year decrease of 38.
89%; net profit attributable to shareholders of listed companies was 1.
104 billion yuan, a year-on-year decrease of 64.
95%; basic earnings per share were 2.
59 yuan
.
Among them, the operating income in the third quarter was 1.
76 billion yuan, a year-on-year decrease of 67.
06%; the net profit attributable to shareholders of listed companies was 343 million yuan, a year-on-year decrease of 83.
8%
.
In addition, on October 25, Zhende Medical disclosed its three-quarter report for 2021, showing that its revenue and net profit attributable to the first three quarters of this year also fell
.
Data shows that Zhende Medical's operating income in the first three quarters of this year was approximately 3.
863 billion yuan, a year-on-year decrease of 52.
41%; the corresponding realized net profit was approximately 483 million yuan, a year-on-year decrease of 77%
.
Regarding the decline in performance and operating income, Zhende Medical made it clear that it was mainly due to the impact of the epidemic in the same period last year.
The company's sales of anti-epidemic protective equipment increased significantly.
However, as the domestic epidemic situation has been effectively controlled, domestic and foreign epidemic prevention products have relatively sufficient production capacity.
, Caused by the return of the price of anti-epidemic protective equipment
.
